NCT01504789 is a NA clinical trial of Baseline Fitness Test in Breast Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01504789?

NCT01504789 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01504789?

Interventions in NCT01504789: Baseline Fitness Test, Questionnaires, Individualized Exercise Program, Written Materials.

What condition does NCT01504789 study?

NCT01504789 studies Breast Cancer.

Is NCT01504789 still recruiting?

NCT01504789 is currently active, enrolled. Last updated 27 October 2025.

Last reviewed 2025-10-27 · How we verify

NCT01504789

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Part II: Exercise in Hispanic Breast Cancer Survivors

Active, enrolled NA Last updated 27 October 2025

What this trial tests

NA trial testing Baseline Fitness Test in Breast Cancer in 53 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 February 2012

Primary endpoint
28 February 2026

28 February 2026

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	53
Start date	7 February 2012
Primary completion	28 February 2026
Estimated completion	28 February 2026
Sites	2 locations across Puerto Rico, United States

Drugs / interventions tested

Baseline Fitness Test
Questionnaires
Individualized Exercise Program
Written Materials

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

21 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this research study is to test an exercise program that is designed for Hispanic breast cancer survivors. Researchers want to learn the most effective strategies for promoting exercise.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dietary Patterns in Puerto Rican and Mexican-American Breast Cancer Survivors: A Pilot Study.
Palacios C, Daniel CR, Tirado-Gómez M, Gonzalez-Mercado V, et al · · 2017 · cited 14× · PMID 26984227 · DOI 10.1007/s10903-016-0398-y

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01504789 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 27 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01504789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing